Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Treating COVID-19 with Chloroquine

Huang et al., Journal of Molecular Cell Biology, Volume 12, Issue 4, April 2020, 322–325, doi:10.1093/jmcb/mjaa014
Apr 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Recovery at day 14 92% Improvement Relative Risk Improvement in pneumon.. 83% HCQ  Huang et al.  EARLY TREATMENT  RCT Is early treatment with HCQ beneficial for COVID-19? RCT 22 patients in China (January - February 2020) Trial compares with lopinavir/ritonavir, results vs. placebo may differ Improved recovery with HCQ (p=0.015) c19hcq.org Huang et al., J. Molecular Cell Biolog.., Apr 2020 FavorsHCQ Favorslopinavir/ri.. 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
22 patients. All CQ patients discharged by day 14 versus 50% of lopinavir/ritonavir patients. Symptom onset was very different - 2.5 days for CQ vs. 6.5 days for lopinavir/ritonavir.
This study is excluded in meta analysis: excessive unadjusted differences between groups.
risk of no recovery at day 14, 91.7% lower, RR 0.08, p = 0.02, treatment 0 of 10 (0.0%), control 6 of 12 (50.0%), NNT 2.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of no improvement in pneumonia at day 14, 83.0% lower, RR 0.17, p = 0.22, treatment 10, control 12.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Huang et al., 1 Apr 2020, Randomized Controlled Trial, China, peer-reviewed, 18 authors, study period 27 January, 2020 - 15 February, 2020, average treatment delay 2.5 days, dosage chloroquine 500mg bid days 1-10, this trial compares with another treatment - results may be better when compared to placebo.
This PaperHCQAll
Treating COVID-19 with Chloroquine
Mingxing Huang, Tiantian Tang, Pengfei Pang, Man Li, Ruolan Ma, Jiahui Lu, Jingxian Shu, Yingying You, Binghui Chen, Jiabi Liang, Zhongsi Hong, Huili Chen, Ling Kong, Dajiang Qin, Duanqing Pei, Jinyu Xia, Shanping Jiang, Hong Shan
Journal of Molecular Cell Biology, doi:10.1093/jmcb/mjaa014
Treating COVID-19 with Chloroquine A novel coronavirus disease 2019 (COVID-19) emerged around December 2019 in Wuhan, China and has spread rapidly worldwide (Lu et al., 2020). Until March 27, 2020, the Chinese health authorities had reported 82082 confirmed COVID-19 cases in China with 3298 deaths and 381443 confirmed cases with 20787 deaths outside China. The World Health Organization (WHO) named the virus SARS-CoV-2, which belongs to a distinct clade from the human severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV) (Zhu et al., 2020). At present, there is no effective therapy against this new virus. Identifying effective antiviral agents to treat the COVID-19 is of most urgency. Coronavirus relies on cellular machinery to replicate itself, thus providing a rationale to search for effective therapies among agents that may impact pathways required for the viral life cycle. The vesicular trafficking system plays a critical role in viral entry, unpacking, assembly, and packaging. Among agents that can interfere with normal vesicular trafficking are several drugs approved for human therapies. A well-known antimalaria drug, Chloroquine, stands out as one of the earliest reagents that can block vesicular trafficking and also interfere with the life cycle of parasites and viruses (Savarino
References
Delvecchio, Higa, Pezzuto, Chloroquine, an endocytosis blocking agent, inhibits Zika virus infection in different cell models, Viruses
Keyaerts, Vijgen, Maes, In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine, Biochem. Biophys. Res. Commun
Kono, Tatsumi, Imai, Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK, Antivir. Res
Lu, Stratton, Tang, Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle, J. Med. Virol
Savarino, Di Trani, Donatelli, New insights into the antiviral effects of chloroquine, Lancet Infect. Dis
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Zhang, Yi, Li, Chloroquine inhibits endosomal viral RNA release and autophagy-dependent viral replication and effectively prevents maternal to fetal transmission of Zika virus, Antivir. Res
Zhou, Yang, Wang, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature
Zhu, Zhang, Wang, A novel coronavirus from patients with pneumonia in China, N. Engl. J. Med
{ 'indexed': {'date-parts': [[2024, 5, 2]], 'date-time': '2024-05-02T12:58:29Z', 'timestamp': 1714654709577}, 'reference-count': 10, 'publisher': 'Oxford University Press (OUP)', 'issue': '4', 'license': [ { 'start': { 'date-parts': [[2020, 4, 2]], 'date-time': '2020-04-02T00:00:00Z', 'timestamp': 1585785600000}, 'content-version': 'vor', 'delay-in-days': 1, 'URL': 'http://creativecommons.org/licenses/by-nc/4.0/'}], 'funder': [ { 'name': 'National Mega Project on Major Infectious Disease Prevention', 'award': ['2017ZX10103011']}, { 'DOI': '10.13039/501100003453', 'name': 'Natural Science Foundation of Guangdong Province', 'doi-asserted-by': 'publisher', 'award': ['2018A030313652']}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2020, 5, 18]]}, 'DOI': '10.1093/jmcb/mjaa014', 'type': 'journal-article', 'created': {'date-parts': [[2020, 3, 30]], 'date-time': '2020-03-30T11:07:28Z', 'timestamp': 1585566448000}, 'page': '322-325', 'source': 'Crossref', 'is-referenced-by-count': 174, 'title': 'Treating COVID-19 with Chloroquine', 'prefix': '10.1093', 'volume': '12', 'author': [ { 'given': 'Mingxing', 'family': 'Huang', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Infectious Diseases, The Fifth Affiliated ' 'Hospital, Sun Yat-sen University (SYSU), Zhuhai 519000, China'}, { 'name': 'Guangdong Provincial Key Laboratory of Biomedical Imaging, The ' 'Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai ' '519000, China'}]}, { 'given': 'Tiantian', 'family': 'Tang', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Respiratory and Critical Care Medicine, Sun ' 'Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou ' '510120, China'}, { 'name': 'Institute of Pulmonary Diseases, Sun Yat-sen University, ' 'Guangzhou 510120, China'}]}, { 'given': 'Pengfei', 'family': 'Pang', 'sequence': 'first', 'affiliation': [ { 'name': 'Guangdong Provincial Key Laboratory of Biomedical Imaging, The ' 'Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai ' '519000, China'}, { 'name': 'Interventional Medical Center, The Fifth Affiliated Hospital, ' 'Sun Yat-Sen University, Zhuhai 519000, China'}]}, { 'given': 'Man', 'family': 'Li', 'sequence': 'first', 'affiliation': [ { 'name': 'Guangdong Provincial Key Laboratory of Biomedical Imaging, The ' 'Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai ' '519000, China'}, { 'name': 'Research Center of Molecular Imaging, The Fifth Affiliated ' 'Hospital, Sun Yat-Sen University, Zhuhai 519000, China'}]}, { 'given': 'Ruolan', 'family': 'Ma', 'sequence': 'first', 'affiliation': [ { 'name': 'Guangzhou Institutes of Biomedicine and Health, Chinese Academy ' 'of Sciences, Guangzhou 510530, China'}, { 'name': 'University of Chinese Academy of Sciences, Beijing 100049, ' 'China'}]}, { 'given': 'Jiahui', 'family': 'Lu', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Infectious Diseases, The Fifth Affiliated ' 'Hospital, Sun Yat-sen University (SYSU), Zhuhai 519000, China'}]}, { 'given': 'Jingxian', 'family': 'Shu', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Pharmacy, The Fifth Affiliated Hospital, Sun ' 'Yat-sen University, Zhuhai 519000, China'}]}, { 'given': 'Yingying', 'family': 'You', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Stomatology, The Fifth Affiliated Hospital, Sun ' 'Yat-sen University, Zhuhai 519000, China'}]}, { 'given': 'Binghui', 'family': 'Chen', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Radiology, The Fifth Affiliated Hospital, Sun ' 'Yat-sen University, Zhuhai 519000, China'}]}, { 'given': 'Jiabi', 'family': 'Liang', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Pharmacy, The Fifth Affiliated Hospital, Sun ' 'Yat-sen University, Zhuhai 519000, China'}]}, { 'given': 'Zhongsi', 'family': 'Hong', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Infectious Diseases, The Fifth Affiliated ' 'Hospital, Sun Yat-sen University (SYSU), Zhuhai 519000, China'}]}, { 'given': 'Huili', 'family': 'Chen', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Infectious Diseases, The Fifth Affiliated ' 'Hospital, Sun Yat-sen University (SYSU), Zhuhai 519000, China'}]}, { 'given': 'Ling', 'family': 'Kong', 'sequence': 'first', 'affiliation': [ { 'name': 'Guangzhou Regenerative Medicine and Health Guangdong Laboratory, ' 'Guangzhou 510700, China'}]}, { 'given': 'Dajiang', 'family': 'Qin', 'sequence': 'first', 'affiliation': [ { 'name': 'Guangzhou Regenerative Medicine and Health Guangdong Laboratory, ' 'Guangzhou 510700, China'}, { 'name': 'Guangzhou Institutes of Biomedicine and Health, Chinese Academy ' 'of Sciences, Guangzhou 510530, China'}]}, { 'given': 'Duanqing', 'family': 'Pei', 'sequence': 'first', 'affiliation': [ { 'name': 'Guangzhou Regenerative Medicine and Health Guangdong Laboratory, ' 'Guangzhou 510700, China'}, { 'name': 'Guangzhou Institutes of Biomedicine and Health, Chinese Academy ' 'of Sciences, Guangzhou 510530, China'}]}, { 'given': 'Jinyu', 'family': 'Xia', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Infectious Diseases, The Fifth Affiliated ' 'Hospital, Sun Yat-sen University (SYSU), Zhuhai 519000, China'}]}, { 'given': 'Shanping', 'family': 'Jiang', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Respiratory and Critical Care Medicine, Sun ' 'Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou ' '510120, China'}, { 'name': 'Institute of Pulmonary Diseases, Sun Yat-sen University, ' 'Guangzhou 510120, China'}]}, { 'given': 'Hong', 'family': 'Shan', 'sequence': 'first', 'affiliation': [ { 'name': 'Guangdong Provincial Key Laboratory of Biomedical Imaging, The ' 'Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai ' '519000, China'}, { 'name': 'Interventional Medical Center, The Fifth Affiliated Hospital, ' 'Sun Yat-Sen University, Zhuhai 519000, China'}]}], 'member': '286', 'published-online': {'date-parts': [[2020, 4, 1]]}, 'reference': [ { 'key': '2020051804580989200_ref1', 'doi-asserted-by': 'crossref', 'DOI': '10.3390/v8120322', 'article-title': 'Chloroquine, an endocytosis blocking agent, inhibits Zika virus ' 'infection in different cell models', 'volume': '8', 'author': 'Delvecchio', 'year': '2016', 'journal-title': 'Viruses'}, { 'key': '2020051804580989200_ref2', 'doi-asserted-by': 'crossref', 'first-page': '264', 'DOI': '10.1016/j.bbrc.2004.08.085', 'article-title': 'In vitro inhibition of severe acute respiratory syndrome coronavirus by ' 'chloroquine', 'volume': '323', 'author': 'Keyaerts', 'year': '2004', 'journal-title': 'Biochem. Biophys. Res. Commun.'}, { 'key': '2020051804580989200_ref3', 'doi-asserted-by': 'crossref', 'first-page': '150', 'DOI': '10.1016/j.antiviral.2007.10.011', 'article-title': 'Inhibition of human coronavirus 229E infection in human epithelial lung ' 'cells (L132) by chloroquine: involvement of p38 MAPK and ERK', 'volume': '77', 'author': 'Kono', 'year': '2008', 'journal-title': 'Antivir. Res.'}, { 'key': '2020051804580989200_ref4', 'doi-asserted-by': 'crossref', 'first-page': '401', 'DOI': '10.1002/jmv.25678', 'article-title': 'Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery ' 'and the miracle', 'volume': '92', 'author': 'Lu', 'year': '2020', 'journal-title': 'J. Med. Virol.'}, { 'key': '2020051804580989200_ref5', 'doi-asserted-by': 'crossref', 'first-page': '67', 'DOI': '10.1016/S1473-3099(06)70361-9', 'article-title': 'New insights into the antiviral effects of chloroquine', 'volume': '6', 'author': 'Savarino', 'year': '2006', 'journal-title': 'Lancet Infect. Dis.'}, { 'key': '2020051804580989200_ref6', 'doi-asserted-by': 'crossref', 'first-page': '269', 'DOI': '10.1038/s41422-020-0282-0', 'article-title': 'Remdesivir and chloroquine effectively inhibit the recently emerged ' 'novel coronavirus (2019-nCoV) in vitro', 'volume': '30', 'author': 'Wang', 'year': '2020', 'journal-title': 'Cell Res.'}, { 'key': '2020051804580989200_ref7', 'author': 'World Health Organization.', 'year': '2020', 'journal-title': 'Clinical management of severe acute respiratory infection when novel ' 'coronavirus (2019-nCoV) infection is suspected: interim guidance'}, { 'key': '2020051804580989200_ref7a', 'doi-asserted-by': 'crossref', 'first-page': '104547', 'DOI': '10.1016/j.antiviral.2019.104547', 'article-title': 'Chloroquine inhibits endosomal viral RNA release and ' 'autophagy-dependent viral replication and effectively prevents maternal ' 'to fetal transmission of Zika virus', 'volume': '169', 'author': 'Zhang', 'year': '2019', 'journal-title': 'Antivir. Res.'}, { 'key': '2020051804580989200_ref8', 'doi-asserted-by': 'crossref', 'first-page': '270', 'DOI': '10.1038/s41586-020-2012-7', 'article-title': 'A pneumonia outbreak associated with a new coronavirus of probable bat ' 'origin', 'volume': '579', 'author': 'Zhou', 'year': '2020', 'journal-title': 'Nature'}, { 'key': '2020051804580989200_ref9', 'doi-asserted-by': 'crossref', 'first-page': '727', 'DOI': '10.1056/NEJMoa2001017', 'article-title': 'A novel coronavirus from patients with pneumonia in China, 2019', 'volume': '382', 'author': 'Zhu', 'year': '2020', 'journal-title': 'N. Engl. J. Med.'}], 'container-title': 'Journal of Molecular Cell Biology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'http://academic.oup.com/jmcb/advance-article-pdf/doi/10.1093/jmcb/mjaa014/33115584/mjaa014.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'http://academic.oup.com/jmcb/article-pdf/12/4/322/33224388/mjaa014.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'syndication'}, { 'URL': 'http://academic.oup.com/jmcb/article-pdf/12/4/322/33224388/mjaa014.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2020, 5, 18]], 'date-time': '2020-05-18T08:58:32Z', 'timestamp': 1589792312000}, 'score': 1, 'resource': {'primary': {'URL': 'https://academic.oup.com/jmcb/article/12/4/322/5814655'}}, 'subtitle': [], 'editor': [{'given': 'Jiarui', 'family': 'Wu', 'sequence': 'first', 'affiliation': []}], 'short-title': [], 'issued': {'date-parts': [[2020, 4, 1]]}, 'references-count': 10, 'journal-issue': { 'issue': '4', 'published-online': {'date-parts': [[2020, 4, 1]]}, 'published-print': {'date-parts': [[2020, 5, 18]]}}, 'URL': 'http://dx.doi.org/10.1093/jmcb/mjaa014', 'relation': {}, 'ISSN': ['1759-4685'], 'subject': [], 'published-other': {'date-parts': [[2020, 4]]}, 'published': {'date-parts': [[2020, 4, 1]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit